LSTM Secretariat

Professor Feiko ter Kuile Principal Investigator
Dr Jenny Hill      Research Programme Manager & Co-investigator
Tracy Seddon   Programme Coordinator






Mwayi Madanitsa 

College of Medicine, Malawi

John Lusingu

National Institute of Medical Research, Tanzania

Pascal Magnussen

University of Copenhagen, Denmark

Michael Alifrangis

University of Copenhagen, Denmark

Christentze Schmiegelow

University of Copenhagen, Denmark

Thor Grundtvig

University of Copenhagen, Denmark

Matt Chico

London School of Hygiene & Tropical Medicine

Jayne Webster

London School of Hygiene & Tropical Medicine

Frank Mosha  

Kilimanjaro Christian Medical Centre, Tanzania

Simon Kariuki  

Kenya Medical Research Institute, Kenya

Bjarne Robberstad

University of Bergen

Nigel Klein

University College London, UK

Ulla Ashorn 

University of Tampere, Finland



To conduct a definitive trial that will determine if IPTp with with dihydroartemisinin-piperaquine (IPRp-DP), either alone or combined with azithromycin (AZ), is a superior efficacious and safe alternative to the existing strategy of IPTp with sulphadoxine-pyrimethamine (SP) for controlling malaria and reducing adverse pregnancy outcomes in areas with high malaria transmission and high SP resistance in East and Southern Africa.

Summary of work

We are undertaking a multi-national, individually-randomized, 3-arm, superiority trial comparing the efficacy, safety and tolerance of IPTp-SP (control) versus IPTp-DP, alone or combined with azithromycin) to reduce the adverse effects of malaria and curable STIs/RTIs in 10 sites in high SP resistance areas in Kenya, Malawi, and Tanzania. The project includes cardiac monitoring for safety, nested studies of antimalarial drug resistance and macrolide resistance, the impact of SP and AZ on vaginal and intestinal microbiota, and health economics, feasibility and acceptability components.

It also includes four African PhD-studentships and a Post-Doctoral fellowship.


This project is part of the EDCTP2 programme supported by the European Union and also funded by the Joint Global Health Trials (MRC, Wellcome Trust, and DFID)